# Orforglipron – 12mg × 100 tablets (Research Use Only)

Backed by the Research [Read: How Incretin and Growth-Hormone-Axis Compounds in the Literature →](https://portaltowellness.net/research/glp1-adjunct-peptide-research-guide/) [Read: Injectable vs. Oral GLP-1: What Researchers Need to Know →](https://portaltowellness.net/research/injectable-vs-oral-glp1-what-researchers-need-to-know/)

### Overview

Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist, representing a major structural departure from the injectable peptide-based GLP-1 agonist class. Unlike semaglutide and other peptide GLP-1 agonists, orforglipron’s non-peptide structure enables oral bioavailability without albumin-binding modifications. This mechanistic distinction has made orforglipron a subject of intense comparative pharmacology research interest, particularly in receptor activation kinetics, downstream signaling profiles, and tissue distribution studies.

### What It Is

Orforglipron (LY3502970) is a synthetic small-molecule GLP-1 receptor agonist with a non-peptide core scaffold. As a non-peptide agonist, orforglipron engages the GLP-1 receptor transmembrane binding domain rather than the extracellular peptide recognition domain used by peptide GLP-1 agonists — a distinction relevant to allosteric and orthosteric receptor pharmacology research.

### Key Research Applications

- Non-peptide GLP-1 receptor activation, binding mode, and downstream signaling research
- Comparative pharmacology vs. peptide GLP-1 agonists (semaglutide, liraglutide) in receptor studies
- Oral small-molecule receptor agonist pharmacokinetics and bioavailability research
- GLP-1 receptor orthosteric vs. allosteric binding site characterization studies
- Insulin secretion, glucagon suppression, and gastric emptying research models
- CNS GLP-1 receptor satiety pathway and hypothalamic activation research
- Comparative metabolic endpoint studies (peptide vs. non-peptide GLP-1R agonists)
- Phase III clinical pharmacology reference data support for receptor biology research

### Technical Specifications

| Compound | Orforglipron (LY3502970) |
| --- | --- |
| Mechanism | Non-Peptide GLP-1 Receptor Agonist |
| Developer | Eli Lilly |
| Purity | ≥98% (supplier specification) |
| Form | Oral tablet (12mg) |
| Quantity | 100 tablets per bottle |
| Oral Bioavailability | Yes (non-peptide structure) |
| Storage | Room temperature, away from moisture and light |

**FOR RESEARCH USE ONLY.** Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

---

Source: https://portaltowellness.net/shop/orforglipron/
Research use only. Terms: https://portaltowellness.net/research-use-only/